08 October 2007

200khz EM Field Slows Brain Tumors: Too bad they don't use the correct frequencies ...

Electricity Can Slow the Progression of Certain Cancers

New research in the August Issue of Physics Today explains how low-intensity electric fields can disrupt the division of cancer cells and slow the growth of brain tumors. The team of researchers used alternating electric fields that shift electric particles in cells back and forth hundreds of thousands of times per second. These low-intensity alternating electric fields were once thought to only heat cells but after several years of experiments, the researchers have shown the fields to disrupt cell division in tumor cells placed on a glass dish.

After studying the effect of electricity in vitro and in labratory animals, the researchers began a small human clinical trial. The technique was applied to ten patients with glioblastoma multiforme, a type of brain cancer with a low survival rate. The researchers fitted the patients with electrodes that applied 200 kHz electric fields to the scalp at regular intervals for up to 18 hours a day. The cancer was observed to be progressing to advanced stages at a much slower rate (a median of 26 weeks) and in some cases even regressed. Typical time for tumor progression is 10 weeks and 3 of the 10 patients were still alive two years after the electrode therapy started.

Electric field therapy is found to have two effects on tumor cells. First, it slows down cell division by disrupting the formation and function of a key cell structure known as the mitotic spindle. Second, the electric field can sometimes cause the daughter cells to self destruct by forcing structures and molecules away from its infrastructure before the cell splits away from its partner . Electrode therapy poses little danger to normal brain tissue, because healthy brain cells do not divide. Researchers are now investigating the possibilities of combining electric fields with low-dose chemotherapy.

03 October 2007

Prostate Cancer Treatment: It's all about the money ...

FDA Officials Sued Over Conflicts of Interests
September 30, 2007. By Evelyn Pringle

Washington, DC: A lawsuit recently filed in a federal court in Ohio against FDA officials on behalf of terminal cancer patients provides a rare window into the inner workings of an agency hijacked by pharmaceutical industry giants and stacked with insiders by President George Bush to guard against any threat to the profits of his top campaign contributors.

The lawsuit's complaint describes a conspiracy orchestrated by top FDA officials to basically drive a small company, Dendreon, out of business with the obvious goal of eliminating competition in what has become a thriving new industry involving the treatment of men with prostate cancer.

The complaint gives the details of a step-by-step plot to sabotage the FDA approval process of Provenge, the first-of-a-kind vaccine that can prolong the lives of men with late-stage cancer.

Note: This treatment involves a vaccine with virtually no side effects which replaces chemotherapy. This is a disruptive technology that could rapidly alter the landscape of cancer treatment. Current business interests will do everything they can to suppress competition from these treatments at the cost of patient lives.